Lessons From Sadhart, ENRICHD, and Other Trials
Bibliographic Data
| ID | 19308043 |
|---|---|
| Authors | Karen E Joynt (Duke University, corresponding author), Christopher M O’Connor (0000-0002-1076-718X), Christopher M OʼConnor |
| Year | 2005 |
| Volume | 67 |
| Pages | S63-S66 |
| Publication date | 2005-05-01 |
| Open Access | No |
| Type | ARTICLE |
| Venue | Psychosomatic Medicine (JOURNAL) |
| Journal identifiers | ISSN: 0033-3174 • E-ISSN: 1534-7796 |
| Publisher | Ovid Technologies (Wolters Kluwer Health) (PUBLISHER) |
| DOI | 10.1097/01.psy.0000163454.25036.fc |
| PMID | 15953805 |
| OpenAlex | W2087725126 |
| Language | EN |
| Citations received | 5 |
| References cited | 29 |
Depression is highly prevalent in patients with cardiovascular disease and is independently associated with a poor prognosis when present. A very important aspect of continued therapeutic advances in this field will be the ability to show a convincing connection between the treatment of depression in patients with heart disease and a reduction in morbidity and mortality associated with the co-occurrence of these conditions. The recent SADHART (Sertraline AntiDepressant Heart Attack Trial) investigation demonstrated that sertraline is safe and efficacious in depressed patients with ischemic heart disease but was underpowered to detect a mortality difference between sertraline and placebo. The ENRICHD (ENhancing Recovery in Coronary Heart Disease) trial showed that cognitive-behavioral therapy is effective for treating depression but had no impact on cardiovascular morbidity or mortality. There are a number of methodologic complexities associated with research regarding depression and cardiovascular disease, including difficulties in the definition and measurement of depression, complexities in the conduction of large-scale trials, ethical considerations surrounding the use of placebo, and interpretation of trial results. In addition, the lack of certainty regarding the pathophysiologic link between depression and cardiovascular disease means that there is a lack of pharmacotherapy targeted specifically at the dysregulated physiology that might explain the increased morbidity and mortality seen when these two conditions occur together. BDI = Beck Depression Inventory; CAD = coronary artery disease; CBT = cognitive behavioral therapy; CGI-I = Clinical Global Impression Improvement; CVD = cardiovascular disease; ECG = electrocardiogram; ENRICHD = Enhancing Recovery in Coronary Heart Disease; HAM-D = Hamilton Depression; HR = hazard ratio; HRV = heart rate variability; HRSD = Hamilton Rating Scale for Depression; MI = myocardial infarction; MIND-IT = Myocardial Infarction and Depression Intervention Trial; NHLBI = National Heart Lung and Blood Institute; SADHART = Sertraline Anti-Depressant Heart Attack Randomized Trial; SSRI = selective serotonin reuptake inhibitor
Alternative medicine · Antidepressant · Cardiology · Clinical trial · Depression (economics) · Disease · Intensive care medicine · Pathology · Pharmacotherapy · Placebo · Psychiatry · Sertraline · Cardiac Health and Mental Health · Cardiac Imaging and Diagnostics · Heart Rate Variability and Autonomic Control · Internal Medicine · Medicine
Effects of Long-Term Sertraline Treatment and Depression on Coronary Artery Atherosclerosis in Premenopausal Female Primates
Variations of Depression Treatment Among Women With Hypertension
Genetic Pleiotropy in Depression and Coronary Artery Disease
Comparison of Treatment Rates of Depression After Stroke Versus Myocardial Infarction
From Feeling Blue to Clinical Depression
Impact of Psychological Factors on the Pathogenesis of Cardiovascular Disease and Implications for Therapy
Depression Following Myocardial Infarction
Change in Heart Rate and Heart Rate Variability During Treatment for Depression in Patients With Coronary Heart Disease
Long-term follow-up of the Ischemic Heart Disease Life Stress Monitoring Program
| Citations per year | 0.24 |
|---|---|
| Citation span | 2005 - 2018 (14) |
| Highly cited | No |